You selected: Hepatology
Chronic liver disease (CLD) and cirrhosis are serious liver conditions but little is known about how they affect ethnic minority populations in the United States. When researchers examined CLD and cirrhosis among different groups, they found that the prevalence of CLD ranged from 3.9 percent in African Americans and Native Hawaiians to 4.1 percent in whites, 6.7 percent in Latinos, and 6.9 percent in Japanese.
The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. Now researchers have developed a novel enzyme immunoassay that accomplishes screening and diagnosis in one simple and affordable step.
Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.
In a follow-up study of children who were vaccinated against hepatitis A virus at ages 6 to 21 months, most children who were vaccinated at 12 or 15 months continued to have anti-hepatitis A antibodies in their blood until at least age 15 to 16 years, and modeling experiments suggested that this protection should persist for at least 30 years.
Researchers have found that a genetic variant is linked with an increased risk of fatty liver disease in obese youth; however, children with the variant tend to have lower total and LDL cholesterol levels.
New research reports that cirrhosis at first diagnosis and antibodies for the soluble liver antigen/liver pancreas antigen (SLA/LP) are major risk factors for poor short- and long-term outcome in patients with autoimmune hepatitis. Results published in Hepatology, a journal of the American Association for the Study of Liver Diseases, also found that patients diagnosed in childhood were at higher risk of relapse, need of a liver transplant, and reduced life expectancy.
Liver diseases affect hundreds of millions of people and cause significant illness and death. A new study indicates that liver scarring (or fibrosis), which can ultimately lead to liver failure, is fairly common.
The American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and in collaboration with the International Antiviral Society-USA (IAS-USA), created online Recommendations for Testing, Managing, and Treating Hepatitis C in 2014 to aid practitioners treating patients infected with hepatitis C virus (HCV). Now an update to the Guidance, with a summary of recommendations regarding treatment with direct-acting antiviral drugs, is published in the AASLD journal, Hepatology.
Treatment options for chronic hepatitis C, a serious and life-threatening infection, have improved substantially and several new regimens with shorter durations and improved efficacy and safety profiles are now available.
Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country. The study, published in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests that effective strategies are need to contain a potential HDV epidemic in these high-risk populations.
New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. However, a new study shows that immediate treatment of HCV-infected patients with moderate or advanced liver scarring is cost-effective. Immediate treatment of patients with minimal or no scarring can be cost-effective as well, particularly when lower treatment costs are assumed.
Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, “Reactivation of Hepatitis B,” and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. Reactivation of HBV can be fatal and the study authors suggest routine screening of HBV in all patients prior to the start of treatment with immunosuppressives or anti-cancer drugs.
A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life’ view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.
New research reports that the rate of hospitalization due to hepatitis A virus (HAV) infection has significantly declined in the U.S. from 2002 to 2011. Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that older patients and those with chronic liver disease are most likely to be hospitalized for HAV. Vaccination of adults with chronic liver disease may prevent infection with hepatitis A and the need for hospitalization.
Researchers from the National Cancer Institute report that decaffeinated coffee drinking may benefit liver health. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that higher coffee consumption, regardless of caffeine content, was linked to lower levels of abnormal liver enzymes. This suggests that chemical compounds in coffee other than caffeine may help protect the liver.
New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period. According to the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, liver injury caused by non-bodybuilding supplements is most severe, occurring more often in middle-aged women and more frequently resulting in death or the need for transplantation than liver injury from bodybuilding supplements or conventional medications.
In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology,a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. Genotype 3, at just over 54 million cases, is the next most prevalent, followed by genotypes 2, 4, 6, and 5.
Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis). According to the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, hypercaloric diet with frequent meals increases intrahepatic triglyceride content (IHTG) and fat around the waist, but increasing meal size did not.
New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, show that tea, fruit juice, and soft drink consumption are not linked to cirrhosis mortality risk. As with previous studies heavy alcohol use was found to increase risk of death from cirrhosis.
Glycerol Phenylbutyrate Reduces Hepatic Encephalopathy Events and Ammonia Levels Compared to Placebo in a Phase 2 Trial
Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to reduce hepatic encephalopathy episodes in patients with cirrhosis, with a safety profile similar to placebo.